ethyl 3-cycloheptyl-3-oxo-2-(2,4,6-trifluorophenyl)propanoate | 847983-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 3-cycloheptyl-3-oxo-2-(2,4,6-trifluorophenyl)propanoate
• CAS: 847983-15-7
• 化学式: C₁₈H₂₁F₃O₃
• 分子量: 342.358
• InChiKey: SZWVYJLZOMWPLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 3-cycloheptyl-3-oxo-2-(2,4,6-trifluorophenyl)propanoate 、 2-吡嗪脒 在 氮气 、 三正丁胺 、 hexanes 、 silica gel 、 甲醇 、 乙酸乙酯 作用下， 以 三正丁胺 为溶剂， 反应 4.0h， 以provides 6-cycloheptyl-2-pyrazin-2-yl-5-(2,4,6-trifluorophenyl)pyrimidin-4-ol as a light yellow solid的产率得到6-cycloheptyl-2-pyrazin-2-yl-5-(2,4,6-trifluorophenyl)pyrimidin-4-ol
  参考文献：
  名称：

  5-arylpyrimidines as anticancer agents

  摘要：

  本发明涉及某些5-芳基嘧啶化合物或其药学上可接受的盐，以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是用于治疗哺乳动物癌症的抗癌剂。本发明进一步涉及一种治疗或抑制哺乳动物癌性肿瘤细胞和相关疾病的方法，并进一步提供一种用于治疗或预防表达多药耐药性（MDR）或因MDR而耐药的癌性肿瘤的方法，该方法包括向所述哺乳动物中施用所述化合物或其药学上可接受的盐的有效量。更具体地，本发明涉及一种通过促进微管聚合来治疗或抑制哺乳动物中需要的癌性肿瘤细胞和相关疾病的方法，该方法包括向所述哺乳动物中施用所述化合物及其药学上可接受的盐的有效量。

  公开号：

  US07524849B2
• 作为产物：
  描述：

  环庚烷羰酰氯 在 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正庚烷 、 乙基苯 为溶剂， 反应 1.0h， 生成 ethyl 3-cycloheptyl-3-oxo-2-(2,4,6-trifluorophenyl)propanoate
  参考文献：
  名称：

  [EN] 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS
  [FR] 6-[(SUBSTITUTEES)PHENYL]TRIAZOLOPYRIMIDINES UTILISEES EN TANT QU'AGENT ANTICANCEREUX

  摘要：

  本发明涉及某些6-[(取代)苯基]三唑吡咯嗪化合物或其药用盐，以及含有所述化合物或其药用盐的组合物，其中所述化合物是对哺乳动物中的癌症具有治疗作用的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，并进一步提供了一种治疗或预防表达多药耐药性（MDR）或因MDR而具有耐药性的癌症肿瘤的方法，该方法包括向该哺乳动物施用所述化合物或其药用盐的有效量。本发明涉及一种通过促进微管聚合来治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，该方法包括向该哺乳动物施用所述化合物及其药用盐的有效量。

  公开号：

  WO2005030775A1

文献信息

• [EN] 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS<br/>[FR] 6-[(SUBSTITUTEES)PHENYL]TRIAZOLOPYRIMIDINES UTILISEES EN TANT QU'AGENT ANTICANCEREUX
  申请人：WYETH CORP

  公开号：WO2005030775A1

  公开（公告）日：2005-04-07

  This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  本发明涉及某些6-[(取代)苯基]三唑吡咯嗪化合物或其药用盐，以及含有所述化合物或其药用盐的组合物，其中所述化合物是对哺乳动物中的癌症具有治疗作用的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，并进一步提供了一种治疗或预防表达多药耐药性（MDR）或因MDR而具有耐药性的癌症肿瘤的方法，该方法包括向该哺乳动物施用所述化合物或其药用盐的有效量。本发明涉及一种通过促进微管聚合来治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，该方法包括向该哺乳动物施用所述化合物及其药用盐的有效量。
• 6-Aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
  申请人：Zhang Nan

  公开号：US20050065167A1

  公开（公告）日：2005-03-24

  This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.

  本发明涉及某些6-芳基-7-卤代咪唑[1,2-a]嘧啶或其药学上可接受的盐以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是抗癌剂，可通过促进微管聚合来治疗哺乳动物的癌症。本发明还涉及一种治疗或抑制哺乳动物中癌细胞的生长和相关疾病的方法，并进一步提供了一种用于治疗或预防表达多药耐药性（MDR）或因MDR而耐药的癌症肿瘤的方法，该方法包括向所述哺乳动物施用所述化合物或其药学上可接受的盐的有效量。
• 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents
  申请人：Zhang Nan

  公开号：US20050090508A1

  公开（公告）日：2005-04-28

  This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  本发明涉及某些6-[(取代)苯基]三唑嘧啶化合物或其药学上可接受的盐，以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是对哺乳动物癌症治疗有用的抗癌剂。本发明还涉及一种用于治疗或抑制哺乳动物中癌细胞肿瘤的生长和相关疾病的方法，并进一步提供了一种用于治疗或预防因多药耐药（MDR）而表达多重药物抗性的癌性肿瘤的方法，该方法包括向所述哺乳动物中需要的部位注射所述化合物或其药学上可接受的盐的有效量。本发明还涉及一种通过促进微管聚合来治疗或抑制哺乳动物中癌细胞肿瘤的生长和相关疾病的方法，该方法包括向所述哺乳动物中注射所述化合物及其药学上可接受的盐的有效量。
• 6-aryl-7-halo-imidazo[1,2-a]pyrimidines as anticancer agents
  申请人：Wyeth Holdings Corporation

  公开号：US07285555B2

  公开（公告）日：2007-10-23

  This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.

  本发明涉及某些6-芳基-7-卤代咪唑[1,2-a]嘧啶或其药学上可接受的盐以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是用于通过促进微管聚合治疗哺乳动物癌症的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物癌症肿瘤细胞和相关疾病的方法，并进一步提供一种用于治疗或预防表达多药耐药性（MDR）的癌症肿瘤或因MDR而耐药的哺乳动物的方法，该方法包括向该哺乳动物施用所述化合物或其药学上可接受的盐的有效量。
• 6-[(substituted)phenyl]triazolopyrimidines as anticancer agents
  申请人：Wyeth

  公开号：US07507739B2

  公开（公告）日：2009-03-24

  This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  本发明涉及某些6-[(取代)苯基]三唑嘧啶化合物或其药学上可接受的盐，以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是用于治疗哺乳动物癌症的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物癌性肿瘤细胞和相关疾病的方法，并进一步提供了一种治疗或预防表达多药耐药性（MDR）或因MDR而产生耐药性的癌性肿瘤的方法，其中该方法包括向该哺乳动物施用所述化合物或其药学上可接受的盐的有效量。本发明涉及一种通过促进微管聚合来治疗或抑制哺乳动物癌性肿瘤细胞和相关疾病的方法，该方法包括向该哺乳动物施用所述化合物及其药学上可接受的盐的有效量。